Key Points
WASHINGTON, Oct 2 (Reuters) - The U.S. Supreme Court on Monday declined to hear a lawsuit by CareDx (CDNA.O) over organ-rejection tests made by Natera (NTRA.O) and Eurofins Viracor (EUFI.PA), turning down another request to revisit the contentious issue of patent eligibility...
The justices turned away CareDx's appeal of a lower court's ruling that invalidated patents that the Brisbane, California-based company had accused its medical diagnostics rivals of infringing..
CareDx sued Austin, Texas-based Natera and Viracor, a Kansas-based subsidiary of Luxembourg's Eurofins Scientific, in 2019, accusing them of infringing patents related to its AlloSure blood test for monitoring kidney transplants..
The patents, which CareDx licenses from Stanford University, cover methods of measuring levels of an organ donor's DNA in a transplant recipient's blood to predict whether their body will reject the organ.. CareDx accused Natera's competing Prospera test and Viracor's TRAC Kidney test of violating its patent rights...
The justices have turned down several appeals related to patent eligibility despite the urgings of the past two presidential administrations and the Federal Circuit, whose 12 active judges asked the Supreme Court in 2019 to take up the issue...
You might be interested in
US Supreme Court rejects computer scientist's lawsuit over AI-generated inventions
25, Apr, 23The U.S. Supreme Court on Monday declined to hear a challenge by computer scientist Stephen Thaler to the U.S. Patent and Trademark Office's refusal to issue patents for inventions his artificial intelligence system created.
AI cannot be patent 'inventor', UK Supreme Court says in landmark ruling
20, Dec, 23Stephen Thaler wanted to be granted two patents in the UK for inventions he says were devised by his "creativity machine" called DABUS. | World News